SRDX (Surmodics) Other Financing: $-3.5 Mil (TTM As of Jun. 2025)


SRDX Surmodics Inc SRDX
51 GF Score
Price $42.98
GF Value $32.10
! 5 Warning Signs
View Full Analysis

What is Surmodics Other Financing?

Surmodics SRDX -0.01% 51 Other Financing is $-3.5 Mil as of Jun. 2025. GuruFocus rates SRDX with a GF Score™ of 51/100 and a GF Value™ of $32.10. The stock has 5 warning signs investors should review.

Surmodics's Other Financing for the three months ended in Jun. 2025 was $-0.0 Mil.

Surmodics's Other Financing for the trailing twelve months (TTM) ended in Jun. 2025 was $-3.5 Mil.

Surmodics Other Financing Historical Data

* Premium members only.

The historical data trend for Surmodics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics Other Financing Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.26 -2.90 -1.62 -2.51 -4.17

Surmodics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -2.12 -1.31 -0.02 -0.03
SRDX
51GF Score
Surmodics Inc SRDX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surmodics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-3.5 Mil mean?
Surmodics (SRDX) has a Other Financing of $-3.5 Mil as of Jun. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Surmodics and its competitors.
Is Surmodics' Other Financing too high?
Surmodics' current Other Financing is $-3.5 Mil. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Other Financing compare to CBLL and OFIX?
Surmodics' Other Financing of $-3.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Surmodics and its competitors. Surmodics's current Other Financing is $-3.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current Other Financing of $-3.5 Mil. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current Other Financing is $-3.5 Mil. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Surmodics (SRDX), the current Other Financing is $-3.5 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surmodics (SRDX) Overvalued in 2026?

Based on GuruFocus' analysis, Surmodics stock appears to be overvalued. The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.

Key valuation signals for SRDX:

  • Other Financing: $-3.5 Mil
  • GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for SRDX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98
Price
$32.10
GF Value